CD274 and non-small cell lung carcinoma: Compared to chemotherapy, immune checkpoint blockade against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has prolonged the overall survival (OS) of advanced NSCLC patients (2–6).